Mr Sean Brian Appleyard, MD | |
Hancock Medical Center--emergency Dept, 149 Drink Water Blvd, Bay St. Loois, MS 39520 | |
(228) 467-8669 | |
Not Available |
Full Name | Mr Sean Brian Appleyard |
---|---|
Gender | Male |
Speciality | Emergency Medicine - Emergency Medical Services |
Location | Hancock Medical Center--emergency Dept, Bay St. Loois, Mississippi |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1730106600 | NPI | - | NPPES |
00110012 | Medicaid | MS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207PE0004X | Emergency Medicine - Emergency Medical Services | 13053 (Mississippi) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Sean Brian Appleyard, MD 15153 King Of Spain Ct, Dallas, TX 75248-6427 Ph: (972) 385-1370 | Mr Sean Brian Appleyard, MD Hancock Medical Center--emergency Dept, 149 Drink Water Blvd, Bay St. Loois, MS 39520 Ph: (228) 467-8669 |
News Archive
The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.
A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.
Mazor Robotics Ltd., the leader in innovative surgical robots and complementary products for spine surgery, signed an agreement for the purchase of a Renaissance system with Richard R. M. Francis, MD, of Spine Associates of Houston and the Houston Orthopedic and Spine Hospital, formerly known as Foundation Surgical Hospital, in Bellaire, Texas.
Houston Methodist cancer researchers are now closer to creating a blood test that can identify breast cancer patients who are at increased risk for developing brain metastasis, and also monitor disease progression and response to therapy in real time.
› Verified 7 days ago